Jennifer Chu is a corporate partner and member of the firm’s Mergers & Acquisitions and Private Equity Groups. Her practice focuses on advising corporations and private equity firms in mergers and acquisitions, joint ventures and other corporate matters, across a broad range of industries with a particular focus on transactions in the healthcare, financial services and insurance industries. Ms. Chu is recommended and recognized as a “Next Generation Lawyer” by The Legal 500 US (2017), where she is described as “very seasoned in handling private equity matters.” She was named a “Rising Star of 2017” by the New York Law Journal.
Ms. Chu publishes and speaks regularly on M&A and private equity matters. She is a contributing author to the annual Health Care Mergers and Acquisitions Answer Book (Practising Law Institute, 2017), an extensive reference guide addressing structuring, regulatory, due diligence and documentation issues in healthcare M&A and licensing transactions. Her recent articles include: co-author of “How Tax Reform Could Impact the Healthcare Industry,” Law360 (November, 2017); “How Section 1332 Waivers Could Impact Health Care Reform,” Law360 (July, 2017); “Shining a Light on GOP Plan for Health Care Reform,” Law360 (March, 2017); “The Outlook For The Pharmaceutical Industry Under Trump,” Law360 (January, 2017); “The Outlook on Drug Pricing: At What Cost?,” Law360 (December, 2016) and “A Closer Look: Increased Cybersecurity Regulations are Impacting the Insurance and Financial Technology Sectors,” Best's Review (June, 2015). She is an Editor of The Debevoise & Plimpton Private Equity Report.
Ms. Chu’s recent speaking engagements include “Indemnification Issues,” Acquiring and Selling the Privately Held Company 2017 (June, 2017) and “Health Care M&A: Three Hot Topics,” PLI One-Hour Briefing (April, 2017).
Ms. Chu joined the firm in 2006. She received her J.D. cum laude from Harvard Law School in 2006, where she served as co-Editor-in-Chief of the Harvard International Law Journal. She received her M.A. with distinction from the University of London in 2002, and her A.B. magna cum laude from Harvard College in 2001.
Ms. Chu is a member of the Bar of New York.
Andrew Bab is a corporate partner and a member of the firm’s Mergers & Acquisitions, Private Equity and Healthcare Groups. Mr. Bab has worked extensively on public and private acquisitions, divestitures and joint ventures, including cross-border transactions for both private equity and corporate clients, as well as licensing arrangements and other corporate transactions. He has experience across many industries, but is particularly active in the healthcare sector. In addition, he frequently advises Deutsche Bank, Guggenheim Securities, J.P. Morgan Securities, Morgan Stanley and other investment banks on major M&A transactions.
Mr. Bab is recognized for M&A and private equity buyouts by The Legal 500 US (2015-2016), where he is described as a “leader in healthcare transactions.” Clients have referred to him as “one of the sharpest legal minds [they] have ever worked with” and have noted that “[h]e consistently impresses with his legal and business instincts.” He is named as one of the 500 leading lawyers in America by Lawdragon (2016) and is also recognized as a leading M&A lawyer by Best Lawyers (2016).
Mr. Bab has written prolifically on a variety of M&A and corporate governance-related topics. He is the co-editor of and contributor to the annual Health Care Mergers and Acquisitions Answer Book (Practising Law Institute, 2016), an extensive reference guide addressing structuring, regulatory, due diligence and documentation issues, among other things, in healthcare M&A and licensing deals. He is the co-author of “Lot Of Inversion Talk, But Do You Know the Basics?” Law360 (2014), author of “Got Financing? You May Have to Extend Your Tender Offer,” The Harvard Law School Forum on Corporate Governance and Financial Regulation (2013); “Contingent Value Rights in Healthcare M&A,” Insights (2011); “Poison Pills,” The Harvard Law School Forum on Corporate Governance and Financial Regulation (2011); “A New Worry,” IR Magazine (2008); and co-author of “Soft Dollars and Other Means of Obtaining Business,” a chapter in the Practising Law Institute treatise Broker-Dealer Regulation (2008); “SEC Proposes Amendments to Cross-Border Tender and Exchange Offer and Business Combination Rules,” BNA Securities Regulation & Law (2008); “Tender Offers: Back in Business,” Corporate Governance (2007); and “Gun Jumping Case vs. Qualcomm Shows Risks for Betrothed Companies,” Corporate Governance (2006). Mr. Bab is the author of “Contingent Value Rights,” Insights (2001) and the co-author of several articles published in The Deal, including “The Revlon Standard” (2007), “Booby Traps” (2003) and “Nerve Tonic” (2003). Mr. Bab is also a frequent speaker on legal developments affecting mergers and acquisitions and on healthcare-related issues.
Mr. Bab joined Debevoise as an associate in 1997 and became a partner in 2002. Mr. Bab received his B.A. magna cum laude from Yale University in 1986, and his J.D. in 1992 from Columbia Law School, where he was a Stone Scholar and Book Review Editor of the Law Review. From 1992 to 1993, Mr. Bab served as law clerk to the Hon. Thomas J. Meskill, U.S. Court of Appeals for the Second Circuit. From 1986 to 1989, Mr. Bab was an investment banker at Lazard Frères & Co.